{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:40Z","timestamp":1787498860817,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Gaucher disease (GD) is a lysosomal storage disorder caused by biallelic GBA1 variants. Epilepsy is uncommon in GD and rarely manifests as progressive myoclonus epilepsy (PME), making early recognition difficult. We describe a 20-year-old man with childhood-onset myoclonus that progressed to drug-resistant generalized seizures and cognitive decline. Video-electroencephalography (VEEG) showed generalized polyspike-wave discharges associated with myoclonic jerks, whereas brain magnetic resonance imaging was initially normal. Cerebrospinal fluid studies, metabolic screening, and autoimmune encephalitis antibody panels were unremarkable. Glucocerebrosidase activity was markedly reduced, and a targeted myoclonic-epilepsy gene panel identified two GBA1 variants: c.907C\u202f&amp;gt;\u202fA (p. Leu303Ile) and c.1505G\u202f&amp;gt;\u202fA (p. Arg502His), indicating a presumed compound-heterozygous state consistent with neuronopathic GD type 3. No hepatosplenomegaly or skeletal abnormalities were detected. Seizure control remained poor despite multiple antiseizure medications and vagus nerve stimulation (VNS). To contextualize this case, we systematically reviewed 22 publications encompassing 71 GD3-PME patients. Most cases presented in childhood, frequently showed typical electrophysiological patterns of generalized or multifocal polyspike-wave discharges, and had early normal MRI followed by later cerebellar or brainstem atrophy. Recurrent compound-heterozygous GBA1 variants, markedly reduced enzyme activity, and poor therapeutic response were common findings. The accompanying systematic review highlights the heterogeneity and therapeutic limitations of GD3-associated PME and underscores the importance of incorporating metabolic and genetic testing into the evaluation of unexplained PME for timely diagnosis and tailored management.<\/jats:p>","DOI":"10.3389\/fnins.2026.1742318","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:09Z","timestamp":1769496069000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Progressive myoclonus epilepsy as an early manifestation of neuronopathic Gaucher disease"],"prefix":"10.3389","volume":"20","author":[{"given":"Zhou","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjuan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Neurology, Yuexi County Hospital","place":["Anqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/nejm198607313150506","article-title":"Progressive myoclonus epilepsies: specific causes and diagnosis","volume":"315","author":"Berkovic","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0065-2660(08)60202-3","article-title":"Gaucher disease","volume":"32","author":"Beutler","year":"1995","journal-title":"Adv. Genet."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","article-title":"A monozygotic twin pair with highly discordant Gaucher phenotypes","volume":"46","author":"Biegstraaten","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1528-1167.2007.01074.x","article-title":"Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase\/miglustat combination","volume":"48","author":"Capablo","year":"2007","journal-title":"Epilepsia"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.ymgmr.2019.100476","article-title":"Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100678","DOI":"10.1016\/j.ymgmr.2020.100678","article-title":"In vitro and in vivo effects of ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy","volume":"25","author":"Ciana","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/15548627.2021.1943177","article-title":"The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy","volume":"18","author":"Deneubourg","year":"2022","journal-title":"Autophagy"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.0013-9580.2004.15904.x","article-title":"Early visual seizures and progressive myoclonus epilepsy in neuronopathic Gaucher disease due to a rare compound heterozygosity (N188S\/S107L)","volume":"45","author":"Filocamo","year":"2004","journal-title":"Epilepsia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/brain\/awp161","article-title":"Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations","volume":"132","author":"Gan-Or","year":"2009","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.semcdb.2004.03.003","article-title":"The pathogenesis of glycosphingolipid storage disorders","volume":"15","author":"Ginzburg","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/nu16233994","article-title":"Ketogenic diet and neuroinflammation: implications for neuroimmunometabolism and therapeutic approaches to refractory epilepsy","volume":"16","author":"Guerreiro","year":"2024","journal-title":"Nutrients"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5041\/rmmj.10446","article-title":"Non-immune hemolysis in Gaucher disease and review of the literature","volume":"12","author":"Hershkop","year":"2021","journal-title":"Rambam Maimonides Med. J."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41582-024-00999-z","article-title":"Gaucher disease provides a unique window into Parkinson disease pathogenesis","volume":"20","author":"Hertz","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00415-024-12439-5","article-title":"Neurological symptoms in adults with Gaucher disease: a systematic review","volume":"271","author":"Imbalzano","year":"2024","journal-title":"J. Neurol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.14336\/AD.2021.1217","article-title":"Effects of ketogenic diet on Neuroinflammation in neurodegenerative diseases","volume":"13","author":"Jiang","year":"2022","journal-title":"Aging Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"175023","DOI":"10.1016\/j.ejphar.2022.175023","article-title":"Update of treatment for Gaucher disease","volume":"926","author":"Kong","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","article-title":"A French experience of type 3 Gaucher disease: phenotypic diversity and neurological outcome of 10 patients","volume":"33","author":"Kraoua","year":"2011","journal-title":"Brain Dev."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3345\/kjp.2012.55.2.48","article-title":"Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups","volume":"55","author":"Lee","year":"2012","journal-title":"Korean J. Pediatr."},{"key":"ref1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ana.410280129","article-title":"Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group","volume":"28","author":"Marseille Consensus Group","year":"1990","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.24945","article-title":"Hyposmia and cognitive impairment in Gaucher disease patients and carriers","volume":"27","author":"McNeill","year":"2012","journal-title":"Mov. Disord."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eplepsyres.2009.02.010","article-title":"Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus","volume":"84","author":"Miyahara","year":"2009","journal-title":"Epilepsy Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"907228","DOI":"10.3389\/fneur.2022.907228","article-title":"Genetic and phenotypic spectrum of Chinese patients with epilepsy and photosensitivity","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Neurol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.braindev.2019.08.005","article-title":"High-frequency component in flash visual evoked potentials in type 3 Gaucher disease","volume":"42","author":"Oguri","year":"2020","journal-title":"Brain Dev."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1203\/01.pdr.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr. Res."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nbd.2018.03.008","article-title":"Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease","volume":"122","author":"Pitcairn","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2020.10.010","article-title":"EEG abnormalities in patients with chronic neuronopathic Gaucher disease: a retrospective review","volume":"131","author":"Poffenberger","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pediatrneurol.2024.03.004","article-title":"Clinical and molecular characteristics of neuronal ceroid Lipofuscinosis in Saudi Arabia","volume":"155","author":"Saleh","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/erm.2020.5","article-title":"Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities","volume":"22","author":"Sanz","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1212\/wnl.46.4.1102","article-title":"Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease","volume":"46","author":"Seeman","year":"1996","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/epd2.20274","article-title":"Eye closure-induced seizures in Gaucher disease and progressive myoclonus epilepsy","volume":"26","author":"Serr\u00e3o","year":"2024","journal-title":"Epileptic Disord."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/jhg.2016.158","article-title":"Norrbottnian clinical variant of Gaucher disease in southern Italy","volume":"62","author":"Sestito","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.immuni.2023.01.008","article-title":"Direct activation of microglia by \u03b2-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease","volume":"56","author":"Shimizu","year":"2023","journal-title":"Immunity"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \"simple\" disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.braindev.2021.12.002","article-title":"Long-term efficacy of low-dose perampanel for progressive myoclonus epilepsy in a patient with Gaucher disease type 3","volume":"44","author":"Tahara","year":"2022","journal-title":"Brain Dev."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2009.08.007","article-title":"Gaucher disease patient with myoclonus epilepsy and a novel mutation","volume":"42","author":"Tajima","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00415-018-9084-4","article-title":"Progressive myoclonus epilepsy in Gaucher disease due to a new Gly-Gly mutation causing loss of an Exonic splicing enhancer","volume":"266","author":"Tonin","year":"2019","journal-title":"J. Neurol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2169\/internalmedicine.1699-23","article-title":"Late-onset myoclonic seizure in a 78-year-old woman with Gaucher disease","volume":"63","author":"Yamaguchi-Takegami","year":"2024","journal-title":"Intern. Med."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42494-024-00168-1","article-title":"Electroencephalogram and phenotype patterns in neuronopathic Gaucher disease patients \u2013 ten years of experience in a single center","volume":"6","author":"Yang","year":"2024","journal-title":"Acta Epileptol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1742318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:32Z","timestamp":1769496092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1742318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":46,"alternative-id":["10.3389\/fnins.2026.1742318"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1742318","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1742318"}}